[vc_row][vc_column width=”1/2″][dt_gap height=”10″][vc_column_text]

CNS Drugs

[/vc_column_text][dt_gap height=”10″][vc_column_text]Challenges of developing CNS drugs

• Every area of drug discovery has challenges, and this is especially true for compounds that act in the brain. Our group has special expertise in discovering CNS drugs.

[/vc_column_text][dt_gap height=”10″][vc_column_text]We have the experience and proven track record to:

• Design compounds that maintain appropriate physicochemical
  parameters (mw, PSA, lipophilicity, etc)
• Improve CNS exposure by improving passive permeability and
  eliminating efflux transporter susceptibility
• Proactively recognize and avoid common latent risks including hERG activity and phospholipidosis.
• Design PET ligands and other receptor occupancy tools

[/vc_column_text][/vc_column][vc_column width=”1/2″][dt_gap height=”10″][vc_column_text][dt_cell width=”1/2″]Therapeutic expertise. We have developed and delivered candidates that reached pre-IND tox
and beyond for targets in these disease areas:

 

• Alzheimer’s disease
• Psychosis
• Depression
• Neuropathic pain

[/dt_cell][dt_cell width=”1/2″]
[/dt_cell][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][dt_gap height=”30″][vc_column_text]References:
Targets and Emerging Therapies for Schizophrenia, 2012, Wiley Press. Edited by Jeffrey S. Albert and Michael W. Wood (Link)[/vc_column_text][/vc_column][/vc_row]